...engagements MedMonitor An up-to-date timeline of FDA approvals that could impact workers' comp View All MedMonitor Information Social Hub Check out our latest posts and activity View All Social Media...
...nausea Imuldosa should not be used in patients with active infections, tuberculosis, malignancies, hypersensitivity, and noninfectious pneumonia. For ongoing coverage of the latest drug approvals and alerts impacting workers’ comp,...
...This comes after reports of serious heart problems and deaths from much higher than recommended doses of loperamide. These adverse events are due to loperamide's increased use as a drug...
...drugs that do not provide hallucinogenic effects – and possibly minimize more addictive elements. The new study tested if the psychedelic compound DOI (2,5-dimethoxy-4-iodoamphetamine) could reduce anxiety in mice by...
The California Division of Workers’ Compensation (DWC) adopted long-awaited Pharmaceutical Fee Schedule rules, introducing major changes to pharmaceutical billing and reimbursement. While there are many updates to the new rules,...
...in the workers’ compensation industry have become experts in managing this particular area of concern, these latest numbers remind us that opioid management continues to be more important than ever....
...To support implementation, the DWC will hold a stakeholder presentation on August 12, 2026, to review the project timeline and discuss training, testing, and other potential changes. Written comments on...
The California Division of Workers' Compensation (DWC) released its annual report on the Independent Medical Review (IMR) program, managed by Maximus Federal Services. IMRs resolve disputes over treatment denials or...
The National Council on Compensation Insurance (NCCI) released its latest Labor Market Insights report, offering a snapshot of current employment trends and their potential impact on workers’ compensation. By highlighting...
...use data from a comparator product approved outside the U.S. as evidence that a proposed product is biosimilar to the U.S.-licensed product. The recommendations describe scenarios in which a biosimilar...
Many clinical trials are underway for drugs to combat COVID-19, but the FDA gave special notice to two drugs. Gilead Sciences initiated two Phase 3 studies of the investigational antiviral...
...used in workers’ comp, and even when used responsibly, opioids come with various risks, including potential overdose and death. Certain high-dose opioids are sometimes even co-prescribed with naloxone medications in...
...submit comments, data or information to the docket. Stakeholders are encouraged to submit comments electronically at regulations.gov by searching for Docket No. FDA-2026-N-10429. The comment period closes Friday, November 20,...
...Alzheimer’s could interfere with medication adherence, particularly if patients also have a comorbidity. For ongoing coverage of the latest drug approvals and alerts impacting workers’ comp, visit Med Monitor online....
...increased dramatically since AMA’s last survey, with nearly 40% of respondents using it within workflows – 26 percentage points higher than 2024. Physician sentiment toward AI continues to trend positive....
